Insights Into the Advantageous Positioning for Europe in Pharmaceutical Cannabis

Read an interview from Pharmaceutical Times Europe exploring how the European bio/pharma industry’s high regulatory standards and GMP requirements are set to position the region as a frontrunner for pharmaceutical grade manufacturing of cannabis-based medicines.

Our sister publication, Pharmaceutical Technology Europe, recently conducted an interview with Michael Sassano, CEO at SOMAÍ Pharmaceuticals, to learn more about the European market and how pharmaceutical applications will shape up in the future.

There are various cannabis or cannabinoid-based products used in pharmacotherapy in Europe, mainly for treating chronic pain, nausea, and vomiting caused by chemotherapy. However, currently only one cannabinoid-based pharmaceutical product has been approved by the European Medicines Agency (EMA) under the centralized procedure, allowing it to be marketed throughout the entire European Union.

Click here to read the full article from Pharmaceutical Technology Europe’s February 2023 issue:

Read more here: Source link

Leave a Reply

Your email address will not be published. Required fields are marked *